Arkolith/Insider Trading/QNRX/Form 4

Dunn Gordon

Chief Financial OfficerQuoin Pharmaceuticals, Ltd. (QNRX) · full profile →Form 4 · filed Dec 27, 2024
Net Buying
Open-Market Buys
$55K
Open-Market Sells
$0
Net Open-Market Flow
$55K
Transactions
3
1 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 23, 2024Buy(P)122K$0.45$55K151K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Dec 23, 2024Buy(P)122K——122K
Dec 23, 2024Buy(P)122K——122K

Transaction Codes

P
Open-market purchase

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001104659-24-132187) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML